Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142

被引：0
|
作者：
Van Cutsem, E. [1 ,2 ]
Dixon, M. [3 ]
Taylor, F. [4 ]
Sun, X. [4 ]
Yip, C. [4 ]
Blum, S. I. [5 ]
机构：
[1] Univ Hosp Gasthuisberg, Digest Oncol, Leuven, Belgium
[2] Katholieke Univ Leuven, Leuven, Belgium
[3] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Lawrenceville, GA USA
[4] Adelphi Values LLC, Patient Centered Outcomes, Boston, MA USA
[5] Bristol Myers Squibb, WW Hlth Econ & Outcomes Res, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.958
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
437P
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [31] Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.
    Overman, Michael J.
    Lonardi, Sara
    Leone, Francesco
    McDermott, Raymond S.
    Morse, Michael A.
    Wong, Ka Yeung Mark
    Neyns, Bart
    Leach, Joseph L.
    Alfonso, Pilar Garcia
    Lee, James J.
    Hill, Andrew
    Lenz, Heinz-Josef
    Desai, Jayesh
    Moss, Rebecca A.
    Cao, Z. Alexander
    Ledeine, Jean-Marie
    Tang, Hao
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [32] Patient-reported outcomes in DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer treated with nivolumab: CheckMate 142
    Michael, Overman
    Shital, Kamble
    Rebecca, Moss
    Fiona, Taylor
    Gregory, Maglinte
    James, Shaw
    Kim, Cocks
    Erin, Mann
    Christine, Yip
    Thierry, Andre
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Pembrolizumab (pembro) for previously treated, microsatellite instabilityehigh (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Le, D. T.
    Diaz, L.
    Kim, T. W.
    Van Cutsem, E.
    Geva, R.
    Jager, D.
    Hara, H.
    Burge, M.
    O'Neil, B.
    Kavan, P.
    Yoshino, T.
    Guimbaud, R.
    Taniguchi, H.
    Elez, E.
    Al-Batran, S-E.
    Boland, P.
    Cui, Y.
    Leconte, P.
    Marinello, P.
    Andre, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S550 - S550
  • [34] SYSTEMATIC AND STRUCTURED REVIEWS OF THE DISEASE BURDEN IN PATIENTS WITH MICROSATELLITE INSTABILITY HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) COLORECTAL CANCER (CRC)
    Amonkar, M.
    Chase, M.
    Takyar, J.
    Sharma, S.
    VALUE IN HEALTH, 2021, 24 : S24 - S24
  • [35] Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma (MEL): Results of a phase II study (CheckMate 069)
    Abernethy, Amy Pickar
    Postow, Michael Andrew
    Chesney, Jason Alan
    Grossmann, Kenneth F.
    Taylor, Fiona
    Coon, Cheryl
    Gilloteau, Isabelle
    Dastani, Homa
    Gagnier, Paul
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
    Vaghi, C.
    Ros Montana, F. J.
    Mambrilla, M.
    Navarro Garces, V.
    Comas, R.
    Salva Ballabrera, F.
    Baraibar Argota, I.
    Saoudi Gonzalez, N.
    Rodriguez Castells, M.
    Garcia Rodriguez, A.
    Alcaraz, A.
    Tabernero, J.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S56 - S57
  • [37] Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
    Overman, Michael J.
    Gelsomino, Fabio
    Aglietta, Massimo
    Wong, Mark
    Limon Miron, Maria Luisa
    Leonard, Gregory
    Garcia-Alfonso, Pilar
    Hill, Andrew G.
    Cubillo Gracian, Antonio
    Van Cutsem, Eric
    El-Rayes, Bassel
    McCraith, Stephen M.
    He, Beilei
    Lei, Ming
    Lonardi, Sara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [38] Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
    Andre, T.
    Amonkar, M.
    Norquist, J.
    Shiu, K-K.
    Kim, T. W.
    Jensen, B. V.
    Jensen, L. H.
    Punt, C. J.
    Smith, D.
    Garcia-Carbonero, R.
    Sevilla, I.
    de la Fouchardiere, C.
    Rivera, F.
    Elez, E.
    Diaz, L. A.
    Yoshino, T.
    Van Cutsem, E.
    Yang, P.
    Farooqui, M. Z. H.
    Le, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S409 - S409
  • [39] Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201
    Ciombor, K. K.
    Hong, S.
    Eng, C.
    Yao, X.
    You, N.
    Das, P.
    Chakravarthy, A.
    O'Dwyer, P. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S104 - S104
  • [40] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345